DB-3Q
Phase 2Biologic
DB-3Q is one of 53 biologic programs targeting Crohn Disease (CD). It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
74 competitors in Crohn's Disease
#DrugCompanyPhaseTrials
1Remicade
Johnson & JohnsonApproved
Humira
NovartisApproved
Entyvio
TakedaApproved
Omvoh
Eli LillyApproved
Trexall
Jazz PharmaceuticalsApproved
Mycobutin
PfizerApproved
Opzelura
PfizerApproved
Calciferol
Jazz PharmaceuticalsApproved
Levulan
Sun Pharmaceutical Industries, Inc.Approved
Lamprene
NovartisApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for DB-3Q. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 2[1]
- Company
- DDirect Biologics, LLC